While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Hims & Hers(NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the week. Several analysts raised their price targets on the specialty ...

Both Hims and Keeps offer viable options for treating hair loss. Choosing between the two could come down to product choice, customer service, and personal preference. Share on Pinterest Find out ...

Shares of HIMS stock traded down $12.05 during mid-day trading on Tuesday, reaching $39.27. 55,471,661 shares of the company’s stock traded hands, compared to its average volume of 20,145,240.

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers Health's latest twelve months ev/ebitda is 179.0x Hims & Hers Health's ev/ebitda decreased in 2023 (-27.8x, +113.6%) and increased in 2022 (-13.0x, -31.1%) and 2024 (179.0x, -743.6%).

In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other stocks that grow firmer despite mixed market sentiment. The stock market kicked off ...

Hims & Hers stock fell by 27% as it announced plans to stop selling commercially available compounded semaglutide. The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales ...

Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...

Hims & Hers Health stock dropped 25% after the FDA announced the end of the semaglutide shortage, impacting Hims' weight loss services revenue. Hims plans to launch a generic version of ...

Hims & Hers Health's stock has surged 205% since my last 'Buy' rating, but its valuation is now stretched, prompting a downgrade to 'Hold'. Some risks include Amazon's aggressive telehealth entry ...

FDA's update led to renewed uncertainty for a growing group of telehealth companies such as Hims & Hers that have built businesses around offering cheaper copies of the branded medications.